Drugs / TMX-049
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03449199 | Apr 2018 → May 2019 | diabetic kidney disease | Teijin America, Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-09-20 | Teijin Pharma Limited | Results 開発医薬品の第Ⅱ相臨床試験の結果について teijin-pharma.co.jp ↗
帝人ファーマ株式会社は、2型糖尿病における糖尿病性腎臓病を対象疾患として開発を進めている医薬品（開発コード：「TMX-049」）について、このたび、米国で実施している第Ⅱ相臨床試験（TMX-049DN-201試験）の有効性に関する主要評価項目を達成しました。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-09-20 | Teijin Pharma Limited | 開発医薬品の第Ⅱ相臨床試験の結果について teijin-pharma.co.jp ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TMX-049 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03449199 ↗ |
| Action | Inhibit | “We conducted a proof-of-concept study to investigate the renal effects of a novel XORI, TMX-049, in patients with DKD and type 2 diabetes.” PMID 35369650 ↗ Jun 2021 |
| Route | Oral | “TMX-049: 40 mg of TMX-049 to be taken orally, once daily” NCT03449199 ↗ |